Pfizer begins study of mRNA flu vaccine
The Hindu
The early-stage trial, conducted in the United States, will test the vaccine in healthy adults ages 65- 85.
Pfizer Inc said on Monday it had dosed the first patient in a trial testing a flu vaccine based on messenger RNA, the same technology used in the COVID-19 shots made by the U.S. drugmaker and BioNTech.
The early-stage trial, conducted in the United States, will test the vaccine in healthy adults ages 65- 85.
"The COVID-19 pandemic allowed us to deliver on the immense scientific opportunity of mRNA. Influenza remains an area where we see a need for vaccines," said Kathrin Jansen, head of vaccine research and development at Pfizer.

The Karnataka government has drafted a comprehensive master plan for the integrated development of Kukke Subrahmanya temple, the State’s highest revenue-generating temple managed by the Hindu Religious Institutions and Charitable Endowments Department. The redevelopment initiative is estimated to cost around ₹254 crore and aims to enhance infrastructure and facilities for devotees.